Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma
- PMID: 33423245
- PMCID: PMC8180377
- DOI: 10.1055/s-0040-1722189
Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma
Abstract
Background: Contemporary incidence data for venous thromboembolism (VTE) from racially diverse populations are limited. The racial distribution of Oklahoma County closely mirrors that of the United States.
Objective: To evaluate VTE incidence and mortality, including demographic and racial subgroups.
Design: Population-based prospective study.
Setting: We conducted VTE surveillance at all relevant tertiary care facilities and outpatient clinics in Oklahoma County, Oklahoma during 2012 to 2014, using both active and passive methods. Active surveillance involved reviewing all imaging reports used to diagnose VTE. Passive surveillance entailed identifying VTE events from hospital discharge data and death certificate records.
Measurements: We used Poisson regression to calculate crude, age-stratified, and age-adjusted incidence and mortality rates per 1,000 population per year and 95% confidence intervals (CIs).
Results: The incidence rate of all VTE was 3.02 (2.92-3.12) for those age ≥18 years and 0.05 (0.04-0.08) for those <18 years. The age-adjusted incidence rates of all VTE, deep vein thrombosis, and pulmonary embolism were 2.47 (95% CI: 2.39-2.55), 1.47 (1.41-1.54), and 0.99 (0.93-1.04), respectively. The age-adjusted VTE incidence and the 30-day mortality rates, respectively, were 0.63 and 0.121 for Asians/Pacific Islanders, 3.25 and 0.355 for blacks, 0.67 and 0.111 for Hispanics, 1.25 and 0.195 for Native Americans, and 2.71 and 0.396 for whites.
Conclusion: The age-adjusted VTE incidence and mortality rates vary substantially by race. The incidence of three per 1,000 adults per year indicates an important disease burden, and is informative of the burden in the U.S.
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Conflict of interest statement
G.E.R. discloses the receipt of consultant fees for consultant services provided to the following companies: Anthos, Bayer, BMS, Boehringer-Ingelheim, Daiichi-Sankyo, Eli Lilly, Janssen, Johnson and Johnson, Merck, Pfizer, Portola, Tetherex, and XaTek. G.E.R. and A.M.W. were recipients of research grants from the CDC. The other authors report no conflicts to disclose.
Figures
References
-
- Kasper W, Konstantinides S, Geibel A. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol. 1997;30(05):1165–1171. - PubMed
-
- Maynard G. Rockville, MD: Agency for Healthcare Research and Quality; 2016. Preventing Hospital-Associated Venous Thromboembolism: a Guide for Effective Quality Improvement. 2nd ed.
-
- Agency for Healthcare Research and Quality Postoperative pulmonary embolism or deep vein thrombosis rate: patient safety indicators #12 2012. Accessed October 2, 2017 at:https://www.qualityindicators.ahrq.gov/Downloads/Modules/PSI/V44/TechSpe...
-
- Silverstein M D, Heit J A, Mohr D N, Petterson T M, O'Fallon W M, Melton L J., III Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(06):585–593. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
